Regulus Therapeutics Inc. (7RG0.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Joseph P. Hagan M.B.A. | CEO & Director | 937.09k | -- | 1969 |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | 670.6k | -- | 1969 |
| Ms. Crispina Calsada CPA | Chief Financial Officer | 589.8k | -- | 1970 |
| Mr. Daniel J. Penksa | VP of Finance & Controller | -- | -- | 1986 |
| Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 507.68k | -- | 1961 |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | -- | -- | -- |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer | -- | -- | -- |
| Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | -- | -- | -- |
Regulus Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 34
Description
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
August 7, 2025 at 8:00 PM UTC
Regulus Therapeutics Inc. Earnings Date
Recent Events
Recent Events Information Not Available